Molecular basis of hypertension side effects induced by sunitinib

Anti-Cancer Drugs

Volumn 22, Issue 1, 2011, Pages 1-8

  Aparicio Gallego, Guadalupe ^a   Afonso Afonso, Francisco J ^b   León Mateos, Luis ^b   Fírvida Pérez, Jose L ^b   Vázquez Estévez, Sergio ^b   Lázaro Quintela, Martín ^b   Ramos Vázquez, Manuel ^b   Fernández Calvo, Ovidio ^b   Campos Balea, Begoña ^b   Antón Aparicio, Luis M ^a  

^a UNIVERSITY OF A CORUÑA   (Spain)

^b Grupo Gallego de Investigación Oncológica Genitourinario   (Spain)

Author keywords

Hypertension; Nitric oxide; Sunitinib; Tyrosine kinase inhibitors

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; SUNITINIB; VASCULOTROPIN;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DISEASE SEVERITY; HUMAN; HYPERTENSION; INCIDENCE; NERVE CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; HUMANS; HYPERTENSION; INDOLES; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 78650515560     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283403806     Document Type: Review

References (68)

1. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta Oncol 2009; 48:9-17.
2. Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinid induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007; 18:1745-1747.
3. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. Neutralizations of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278:12605-12608.
4. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies. Oncologist 2008; 13:1084-1096.
5. Cancer therapy evaluation program, common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. 31 March 2003 (http://ctep.cancer.gov). Publish Date: 9 August 2006.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003; 289:2560-2571.
7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
8. Prout GR,Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: A population-based study. Cancer 2005; 104:1638-1647.
9. Demetri GD, Van Oosterom AT, Blackstein M, Garrett C, Shah M, Heinrich M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. J Clin Oncol (ASCO Annual Meeting Proceedings) 2005; 23 (Suppl):4000.
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
11. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
12. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and metaanalysis. Lancet Oncol 2008; 9:117-123.
13. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib therapy. Ann Oncol 2007; 18:1117-1125.
14. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008; 358:95-97.
15. Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencophalopathy syndrome induced by sunitinbib. J Clin Oncol 2007; 35:3559.
16. Folkow B. 'Structural factor' in primary and secondary hypertension. Hypertension 1990; 16:89-101.
17. Struijker-Boudier HAJ, Le Noble JLML, Messing MWJ, Huijberts MSP, Le Noble FAC, Van Essen H. The microcirculation and hypertension. J Hypertens 1992; 10 (Suppl):S147-S156.
18. Greene AS. Microvascular regulation and dysregulation. In: Izzo JI, Black HR, editors. Hypertension primer: The essentials of high blood pressure. 3rd ed. Baltimore: Lippincott Williams & Wilkins; 2003. pp. 183-185.
19. Sullivan JM, Prewitt RL, Josphes JA. Attenuation of the microcirculation in young patients with high-output borderline hypertension. Hypertension 1993; 5:844-851.
20. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV, et al. Impaired microvascular dilation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 1997; 99:1873-1189.
21. Veronese ML, Flahert KT, Townsend R, Mosenkis A, Zimmer R, Rosen M, et al. Pharmacodynamic study of the rat kinase inhibitor BAY 43-9006: Mechanisms of hypertension. J Clin Oncol (Meeting Abstracts) 2004; 22:2035.
22. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
23. Gardiner SM, Compton AM, Bennett T, Palmer RM, Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15:486-492.
24. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274:H1054-H1058.
25. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY. Endothelial damage and angiogenesis in hypertensive patients: Relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003; 16:11-20.
26. Horowitz JR, Rivard A, Van der Zee R, Hariawala M, Sheriff DD, Esakof DD, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997; 17:2793-2800.
27. Sane DC, Anton L, Brosnihan KP. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7:193-201.
28. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69 (Suppl):S25-S33.
29. Mourad JJ, Des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19:927-934.
30. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006; 24:e48.
31. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. Role of RAF in vascular protection from distinct apoptotic stimuli. Science 2003; 301:94-96.
32. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012.
33. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1992; 89:6348-6352.
34. Sander M, Chavoshan B, Victro RG. A large blood pressure-raising effect of nitric synthase inhibition in humans. Hypertension 1999; 33:937-942.
35. 2+-independent nitric oxide synthases. FEBS Lett 1991; 291: 145-149.
36. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330:1431-1438.
37. Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48:20-32.
38. Uwabo J, Soma M, Nakayama T, Kanmatsue K. Association of a variable number of tandem repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in Japanese. Am J Hypertens 1998; 11:125-128.
39. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991; 17:187-193.
40. Awolesi MA, Widman MD, Sessa WC, Sumpio BE. Cyclic strain increases endothelial nitric oxide synthase activity. Surgery 1994; 116:439-444.
41. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO. Impaired endothelium-dependent vasodilation in patients with essential hypertension evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995; 91:1732-1738.
42. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44:1-80.
43. Minshall RD, Erdös EG, Vogel SM. Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Am J Cardiol 1997; 80:132A-136A.
44. Calver A, Collier J, Moncada S, Wallance P. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: The nitric oxide dilator mechanism appear abnormal. J Hypertens 1992; 10:1025-1031.
45. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endotheliumderived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87:1468-1474.
46. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990; 81:1762-1767.
47. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
48. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94:1298-1303.
49. Cockcroft JR, Chowwienczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 1994; 330:1036-1040.
50. Kneale BJ, Chowienczyk PJ, Brett SE, Cockcroft JR, Ritter JM. Forearm vasocontriction in response to noradrenaline and NGmonomethyl- L-arginine in essential hypertension. Clin Sci (Lond) 1999; 97:277-282.
51. Chowdhary S, Townend JN. Role of nitric oxide in the regulation of cardiovascular autonomic control. Clin Sci (Lond) 1999; 97:5-17.
52. Chowdhary S, Townend JN. Nitric oxide and hypertension: Not just an endothelium derived relaxing factor. J Hum Hypertension 2001; 15:219-227.
53. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 1990; 347:768-770.
54. Vincent SR, Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 1992; 46:755-784.
55. Tseng CJ, Liu HY, Lin HC, Ger LP, Tung CS, Yen MH. Cardiovascular effects of nitric oxide in the brain stem nuclei of rats. Hypertension 1996; 27:36-42.
56. Nakaki T, Hishikawa K, Suzuki H, Sarute T, Kato R. L-arginine induced hypotension. Lancet 1990; 336:696.
57. Ribeiro MO, Antunes E, De-Nucci G, Lovisolo SM, Zata R. Chronic inhibition of nitric oxide synthase, A new model of arterial hypertension. Hypertension 1992; 20:298-303.
58. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993; 11:375-380.
59. Wallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 1992; 339:572-575.
60. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981; 218:739-749.
61. Bahadur MM, Aggarwal VD, Mali M, Thamba A. Novel therapeutic option in hypertensive crisis: Sildenafil augments nitroprusside-induced hypotension. Nephrol Dial Transplant 2005; 20:1254-1256.
62. Bhorjani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53:917-930.
63. Porta C, Szcylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 2009; 35:297-207.
64. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: Recommendations for management of side effects. Cancer Urol Assoc J 2007; 1 (Suppl):S41-S54.
65. Lacy CF, Armstrong LL, Goldman MP. Cytochrome P-450 enzymes and drug metabolism. In: Lacy CF, Armstrong LL, Goldman MP, editors. Drug information handbook. 12th ed. Hudson, Ohio: Lexi-Comp; 2004. pp. 1619-1631.
66. Motzer RJ, Figlin RA, Hutson P, Tomczak TE, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa (INF-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognosis factors. J Clin Oncol 2007; 25 (Suppl.):S241.
67. Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf 1996; 15:91-106.
68. Cross BW, Kirby MG, Miller S, Shah S, Sheldon DM, Sweeney MT. A multicentre study of the safety and efficacy of amylodipine in mild to moderate hypertension. Br J Clin Pract 1993; 47:237-240.